Eradication of Biofilm-Mediated Methicillin-Resistant Staphylococcus aureus Infections In Vitro : Bacteriophage-Antibiotic Combination
Biofilm-associated multidrug-resistant infections pose significant challenges for antibiotic therapy. The extracellular polymeric matrix of biofilms presents an impediment for antibiotic diffusion, facilitating the emergence of multidrug-resistant populations. Bacterial biofilms are difficult to era...
Saved in:
| Published in: | Microbiology spectrum Vol. 10; no. 2; p. e0041122 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
American Society for Microbiology
27.04.2022
|
| Subjects: | |
| ISSN: | 2165-0497, 2165-0497 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Biofilm-associated multidrug-resistant infections pose significant challenges for antibiotic therapy. The extracellular polymeric matrix of biofilms presents an impediment for antibiotic diffusion, facilitating the emergence of multidrug-resistant populations.
Bacterial biofilms are difficult to eradicate and can complicate many infections by forming on tissues and medical devices. Phage+antibiotic combinations (PAC) may be more active on biofilms than either type of agent alone, but it is difficult to predict which PAC regimens will be reliably effective. To establish a method for screening PAC combinations against
Staphylococcus aureus
biofilms, we conducted biofilm time-kill analyses (TKA) using various combinations of phage Sb-1 with clinically relevant antibiotics. We determined the activity of PAC against biofilm versus planktonic bacteria and investigated the emergence of resistance during (24 h) exposure to PAC. As expected, fewer treatment regimens were effective against biofilm than planktonic bacteria. In experiments with isogenic strain pairs, we also saw less activity of PACs against DNS-VISA mutants versus their respective parentals. The most effective treatment against both biofilm and planktonic bacteria was the phage+daptomycin+ceftaroline regimen, which met our stringent definition of bactericidal activity (>3 log
10
CFU/mL reduction). With the VISA-DNS strain 8015 and DNS strain 684, we detected anti-biofilm synergy between Sb-1 and DAP in the phage+daptomycin regimen (>2 log
10
CFU/mL reduction versus best single agent). We did not observe any bacterial resensitization to antibiotics following treatment, but phage resistance was avoided after exposure to PAC regimens for all tested strains. The release of bacterial membrane vesicles tended to be either unaffected or reduced by the various treatment regimens. Interestingly, phage yields from certain biofilm experiments were greater than from similar planktonic experiments, suggesting that Sb-1 might be more efficiently propagated on biofilm.
IMPORTANCE
Biofilm-associated multidrug-resistant infections pose significant challenges for antibiotic therapy. The extracellular polymeric matrix of biofilms presents an impediment for antibiotic diffusion, facilitating the emergence of multidrug-resistant populations. Some bacteriophages (phages) can move across the biofilm matrix, degrade it, and support antibiotic penetration. However, little is known about how phages and their hosts interact in the biofilm environment or how different phage+antibiotic combinations (PACs) impact biofilms in comparison to the planktonic state of bacteria, though scattered data suggest that phage+antibiotic synergy occurs more readily under biofilm-like conditions. Our results demonstrated that phage Sb-1 can infect MRSA strains both in biofilm and planktonic states and suggested PAC regimens worthy of further investigation as adjuncts to antibiotics. |
|---|---|
| AbstractList | Bacterial biofilms are difficult to eradicate and can complicate many infections by forming on tissues and medical devices. Phage+antibiotic combinations (PAC) may be more active on biofilms than either type of agent alone, but it is difficult to predict which PAC regimens will be reliably effective. To establish a method for screening PAC combinations against Staphylococcus aureus biofilms, we conducted biofilm time-kill analyses (TKA) using various combinations of phage Sb-1 with clinically relevant antibiotics. We determined the activity of PAC against biofilm versus planktonic bacteria and investigated the emergence of resistance during (24 h) exposure to PAC. As expected, fewer treatment regimens were effective against biofilm than planktonic bacteria. In experiments with isogenic strain pairs, we also saw less activity of PACs against DNS-VISA mutants versus their respective parentals. The most effective treatment against both biofilm and planktonic bacteria was the phage+daptomycin+ceftaroline regimen, which met our stringent definition of bactericidal activity (>3 log
CFU/mL reduction). With the VISA-DNS strain 8015 and DNS strain 684, we detected anti-biofilm synergy between Sb-1 and DAP in the phage+daptomycin regimen (>2 log
CFU/mL reduction versus best single agent). We did not observe any bacterial resensitization to antibiotics following treatment, but phage resistance was avoided after exposure to PAC regimens for all tested strains. The release of bacterial membrane vesicles tended to be either unaffected or reduced by the various treatment regimens. Interestingly, phage yields from certain biofilm experiments were greater than from similar planktonic experiments, suggesting that Sb-1 might be more efficiently propagated on biofilm.
Biofilm-associated multidrug-resistant infections pose significant challenges for antibiotic therapy. The extracellular polymeric matrix of biofilms presents an impediment for antibiotic diffusion, facilitating the emergence of multidrug-resistant populations. Some bacteriophages (phages) can move across the biofilm matrix, degrade it, and support antibiotic penetration. However, little is known about how phages and their hosts interact in the biofilm environment or how different phage+antibiotic combinations (PACs) impact biofilms in comparison to the planktonic state of bacteria, though scattered data suggest that phage+antibiotic synergy occurs more readily under biofilm-like conditions. Our results demonstrated that phage Sb-1 can infect MRSA strains both in biofilm and planktonic states and suggested PAC regimens worthy of further investigation as adjuncts to antibiotics. Biofilm-associated multidrug-resistant infections pose significant challenges for antibiotic therapy. The extracellular polymeric matrix of biofilms presents an impediment for antibiotic diffusion, facilitating the emergence of multidrug-resistant populations. Bacterial biofilms are difficult to eradicate and can complicate many infections by forming on tissues and medical devices. Phage+antibiotic combinations (PAC) may be more active on biofilms than either type of agent alone, but it is difficult to predict which PAC regimens will be reliably effective. To establish a method for screening PAC combinations against Staphylococcus aureus biofilms, we conducted biofilm time-kill analyses (TKA) using various combinations of phage Sb-1 with clinically relevant antibiotics. We determined the activity of PAC against biofilm versus planktonic bacteria and investigated the emergence of resistance during (24 h) exposure to PAC. As expected, fewer treatment regimens were effective against biofilm than planktonic bacteria. In experiments with isogenic strain pairs, we also saw less activity of PACs against DNS-VISA mutants versus their respective parentals. The most effective treatment against both biofilm and planktonic bacteria was the phage+daptomycin+ceftaroline regimen, which met our stringent definition of bactericidal activity (>3 log 10 CFU/mL reduction). With the VISA-DNS strain 8015 and DNS strain 684, we detected anti-biofilm synergy between Sb-1 and DAP in the phage+daptomycin regimen (>2 log 10 CFU/mL reduction versus best single agent). We did not observe any bacterial resensitization to antibiotics following treatment, but phage resistance was avoided after exposure to PAC regimens for all tested strains. The release of bacterial membrane vesicles tended to be either unaffected or reduced by the various treatment regimens. Interestingly, phage yields from certain biofilm experiments were greater than from similar planktonic experiments, suggesting that Sb-1 might be more efficiently propagated on biofilm. IMPORTANCE Biofilm-associated multidrug-resistant infections pose significant challenges for antibiotic therapy. The extracellular polymeric matrix of biofilms presents an impediment for antibiotic diffusion, facilitating the emergence of multidrug-resistant populations. Some bacteriophages (phages) can move across the biofilm matrix, degrade it, and support antibiotic penetration. However, little is known about how phages and their hosts interact in the biofilm environment or how different phage+antibiotic combinations (PACs) impact biofilms in comparison to the planktonic state of bacteria, though scattered data suggest that phage+antibiotic synergy occurs more readily under biofilm-like conditions. Our results demonstrated that phage Sb-1 can infect MRSA strains both in biofilm and planktonic states and suggested PAC regimens worthy of further investigation as adjuncts to antibiotics. Bacterial biofilms are difficult to eradicate and can complicate many infections by forming on tissues and medical devices. Phage+antibiotic combinations (PAC) may be more active on biofilms than either type of agent alone, but it is difficult to predict which PAC regimens will be reliably effective. To establish a method for screening PAC combinations against Staphylococcus aureus biofilms, we conducted biofilm time-kill analyses (TKA) using various combinations of phage Sb-1 with clinically relevant antibiotics. We determined the activity of PAC against biofilm versus planktonic bacteria and investigated the emergence of resistance during (24 h) exposure to PAC. As expected, fewer treatment regimens were effective against biofilm than planktonic bacteria. In experiments with isogenic strain pairs, we also saw less activity of PACs against DNS-VISA mutants versus their respective parentals. The most effective treatment against both biofilm and planktonic bacteria was the phage+daptomycin+ceftaroline regimen, which met our stringent definition of bactericidal activity (>3 log10 CFU/mL reduction). With the VISA-DNS strain 8015 and DNS strain 684, we detected anti-biofilm synergy between Sb-1 and DAP in the phage+daptomycin regimen (>2 log10 CFU/mL reduction versus best single agent). We did not observe any bacterial resensitization to antibiotics following treatment, but phage resistance was avoided after exposure to PAC regimens for all tested strains. The release of bacterial membrane vesicles tended to be either unaffected or reduced by the various treatment regimens. Interestingly, phage yields from certain biofilm experiments were greater than from similar planktonic experiments, suggesting that Sb-1 might be more efficiently propagated on biofilm. IMPORTANCE Biofilm-associated multidrug-resistant infections pose significant challenges for antibiotic therapy. The extracellular polymeric matrix of biofilms presents an impediment for antibiotic diffusion, facilitating the emergence of multidrug-resistant populations. Some bacteriophages (phages) can move across the biofilm matrix, degrade it, and support antibiotic penetration. However, little is known about how phages and their hosts interact in the biofilm environment or how different phage+antibiotic combinations (PACs) impact biofilms in comparison to the planktonic state of bacteria, though scattered data suggest that phage+antibiotic synergy occurs more readily under biofilm-like conditions. Our results demonstrated that phage Sb-1 can infect MRSA strains both in biofilm and planktonic states and suggested PAC regimens worthy of further investigation as adjuncts to antibiotics. ABSTRACT Bacterial biofilms are difficult to eradicate and can complicate many infections by forming on tissues and medical devices. Phage+antibiotic combinations (PAC) may be more active on biofilms than either type of agent alone, but it is difficult to predict which PAC regimens will be reliably effective. To establish a method for screening PAC combinations against Staphylococcus aureus biofilms, we conducted biofilm time-kill analyses (TKA) using various combinations of phage Sb-1 with clinically relevant antibiotics. We determined the activity of PAC against biofilm versus planktonic bacteria and investigated the emergence of resistance during (24 h) exposure to PAC. As expected, fewer treatment regimens were effective against biofilm than planktonic bacteria. In experiments with isogenic strain pairs, we also saw less activity of PACs against DNS-VISA mutants versus their respective parentals. The most effective treatment against both biofilm and planktonic bacteria was the phage+daptomycin+ceftaroline regimen, which met our stringent definition of bactericidal activity (>3 log10 CFU/mL reduction). With the VISA-DNS strain 8015 and DNS strain 684, we detected anti-biofilm synergy between Sb-1 and DAP in the phage+daptomycin regimen (>2 log10 CFU/mL reduction versus best single agent). We did not observe any bacterial resensitization to antibiotics following treatment, but phage resistance was avoided after exposure to PAC regimens for all tested strains. The release of bacterial membrane vesicles tended to be either unaffected or reduced by the various treatment regimens. Interestingly, phage yields from certain biofilm experiments were greater than from similar planktonic experiments, suggesting that Sb-1 might be more efficiently propagated on biofilm. IMPORTANCE Biofilm-associated multidrug-resistant infections pose significant challenges for antibiotic therapy. The extracellular polymeric matrix of biofilms presents an impediment for antibiotic diffusion, facilitating the emergence of multidrug-resistant populations. Some bacteriophages (phages) can move across the biofilm matrix, degrade it, and support antibiotic penetration. However, little is known about how phages and their hosts interact in the biofilm environment or how different phage+antibiotic combinations (PACs) impact biofilms in comparison to the planktonic state of bacteria, though scattered data suggest that phage+antibiotic synergy occurs more readily under biofilm-like conditions. Our results demonstrated that phage Sb-1 can infect MRSA strains both in biofilm and planktonic states and suggested PAC regimens worthy of further investigation as adjuncts to antibiotics. Bacterial biofilms are difficult to eradicate and can complicate many infections by forming on tissues and medical devices. Phage+antibiotic combinations (PAC) may be more active on biofilms than either type of agent alone, but it is difficult to predict which PAC regimens will be reliably effective. To establish a method for screening PAC combinations against Staphylococcus aureus biofilms, we conducted biofilm time-kill analyses (TKA) using various combinations of phage Sb-1 with clinically relevant antibiotics. We determined the activity of PAC against biofilm versus planktonic bacteria and investigated the emergence of resistance during (24 h) exposure to PAC. As expected, fewer treatment regimens were effective against biofilm than planktonic bacteria. In experiments with isogenic strain pairs, we also saw less activity of PACs against DNS-VISA mutants versus their respective parentals. The most effective treatment against both biofilm and planktonic bacteria was the phage+daptomycin+ceftaroline regimen, which met our stringent definition of bactericidal activity (>3 log10 CFU/mL reduction). With the VISA-DNS strain 8015 and DNS strain 684, we detected anti-biofilm synergy between Sb-1 and DAP in the phage+daptomycin regimen (>2 log10 CFU/mL reduction versus best single agent). We did not observe any bacterial resensitization to antibiotics following treatment, but phage resistance was avoided after exposure to PAC regimens for all tested strains. The release of bacterial membrane vesicles tended to be either unaffected or reduced by the various treatment regimens. Interestingly, phage yields from certain biofilm experiments were greater than from similar planktonic experiments, suggesting that Sb-1 might be more efficiently propagated on biofilm. IMPORTANCE Biofilm-associated multidrug-resistant infections pose significant challenges for antibiotic therapy. The extracellular polymeric matrix of biofilms presents an impediment for antibiotic diffusion, facilitating the emergence of multidrug-resistant populations. Some bacteriophages (phages) can move across the biofilm matrix, degrade it, and support antibiotic penetration. However, little is known about how phages and their hosts interact in the biofilm environment or how different phage+antibiotic combinations (PACs) impact biofilms in comparison to the planktonic state of bacteria, though scattered data suggest that phage+antibiotic synergy occurs more readily under biofilm-like conditions. Our results demonstrated that phage Sb-1 can infect MRSA strains both in biofilm and planktonic states and suggested PAC regimens worthy of further investigation as adjuncts to antibiotics.Bacterial biofilms are difficult to eradicate and can complicate many infections by forming on tissues and medical devices. Phage+antibiotic combinations (PAC) may be more active on biofilms than either type of agent alone, but it is difficult to predict which PAC regimens will be reliably effective. To establish a method for screening PAC combinations against Staphylococcus aureus biofilms, we conducted biofilm time-kill analyses (TKA) using various combinations of phage Sb-1 with clinically relevant antibiotics. We determined the activity of PAC against biofilm versus planktonic bacteria and investigated the emergence of resistance during (24 h) exposure to PAC. As expected, fewer treatment regimens were effective against biofilm than planktonic bacteria. In experiments with isogenic strain pairs, we also saw less activity of PACs against DNS-VISA mutants versus their respective parentals. The most effective treatment against both biofilm and planktonic bacteria was the phage+daptomycin+ceftaroline regimen, which met our stringent definition of bactericidal activity (>3 log10 CFU/mL reduction). With the VISA-DNS strain 8015 and DNS strain 684, we detected anti-biofilm synergy between Sb-1 and DAP in the phage+daptomycin regimen (>2 log10 CFU/mL reduction versus best single agent). We did not observe any bacterial resensitization to antibiotics following treatment, but phage resistance was avoided after exposure to PAC regimens for all tested strains. The release of bacterial membrane vesicles tended to be either unaffected or reduced by the various treatment regimens. Interestingly, phage yields from certain biofilm experiments were greater than from similar planktonic experiments, suggesting that Sb-1 might be more efficiently propagated on biofilm. IMPORTANCE Biofilm-associated multidrug-resistant infections pose significant challenges for antibiotic therapy. The extracellular polymeric matrix of biofilms presents an impediment for antibiotic diffusion, facilitating the emergence of multidrug-resistant populations. Some bacteriophages (phages) can move across the biofilm matrix, degrade it, and support antibiotic penetration. However, little is known about how phages and their hosts interact in the biofilm environment or how different phage+antibiotic combinations (PACs) impact biofilms in comparison to the planktonic state of bacteria, though scattered data suggest that phage+antibiotic synergy occurs more readily under biofilm-like conditions. Our results demonstrated that phage Sb-1 can infect MRSA strains both in biofilm and planktonic states and suggested PAC regimens worthy of further investigation as adjuncts to antibiotics. |
| Author | Lev, Katherine L. Holger, Dana J. Morrisette, Taylor Kunz Coyne, Ashlan J. Lehman, Susan M. Rybak, Michael J. Stamper, Kyle C. Shah, Rahi M. Kebriaei, Razieh |
| Author_xml | – sequence: 1 givenname: Razieh orcidid: 0000-0003-4019-2679 surname: Kebriaei fullname: Kebriaei, Razieh organization: Anti-Infective Research Laboratory, College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA – sequence: 2 givenname: Katherine L. surname: Lev fullname: Lev, Katherine L. organization: Anti-Infective Research Laboratory, College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA – sequence: 3 givenname: Rahi M. surname: Shah fullname: Shah, Rahi M. organization: Anti-Infective Research Laboratory, College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA – sequence: 4 givenname: Kyle C. surname: Stamper fullname: Stamper, Kyle C. organization: Anti-Infective Research Laboratory, College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA – sequence: 5 givenname: Dana J. orcidid: 0000-0001-7171-7015 surname: Holger fullname: Holger, Dana J. organization: Anti-Infective Research Laboratory, College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA – sequence: 6 givenname: Taylor orcidid: 0000-0002-1094-043X surname: Morrisette fullname: Morrisette, Taylor organization: Anti-Infective Research Laboratory, College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA – sequence: 7 givenname: Ashlan J. orcidid: 0000-0002-4891-8625 surname: Kunz Coyne fullname: Kunz Coyne, Ashlan J. organization: Anti-Infective Research Laboratory, College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA – sequence: 8 givenname: Susan M. surname: Lehman fullname: Lehman, Susan M. organization: Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA – sequence: 9 givenname: Michael J. orcidid: 0000-0003-2220-0081 surname: Rybak fullname: Rybak, Michael J. organization: Anti-Infective Research Laboratory, College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA, School of Medicine, Wayne State University, Detroit, Michigan, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35348366$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kk1v1DAQhiNUREvpD-CCcuSSxXbsfHBAalcFVmqFxNfVGtuTXa8SO9gOUv8Av5vsbhe1SHCakT3zzGvP-zw7cd5hlr2kZEEpa97EEXUK07AghFNaMPYkO2O0EgXhbX3yID_NLmLcEkIoJYIJ9iw7LUXJm7KqzrJf1wGM1ZCsd7nv8ivrO9sPxS0aCwlNfotpY7Xte-uKzxhtTOBS_iXBuLnrvfZaTzGHKeAcVq6bNc2kXZp_tyn4_G1-BTphsH7cwBqLS5essj5ZnS_9oKzbj36RPe2gj3hxH8-zb--vvy4_FjefPqyWlzcFCMJTYVojeIek4RWQhlVGmA5ojXWltMaW10SxrjIloR1tiQGhBJS8RkJN04mGl-fZ6sA1HrZyDHaAcCc9WLk_8GEtIczaepQKFFVMibbWlFNgqmRt0_KK8Fog8GpmvTuwxkkNaDS6FKB_BH184-xGrv1P2RIuaLUT8_oeEPyPCWOSg40a-x4c-ilKVnE-v6lud7MWh1KIA5NbPwU3f5OkRO68II9ekHsvSMbmhlcPxf1Rddz8XFAfCnTwMQbspLZpv4tZq-3_i6Z_dR7h_-75DT9X2i0 |
| CitedBy_id | crossref_primary_10_1080_13543776_2025_2545784 crossref_primary_10_1002_phar_2806 crossref_primary_10_1128_aac_01388_23 crossref_primary_10_1186_s40001_025_02781_3 crossref_primary_10_3390_v15041020 crossref_primary_10_1128_spectrum_04918_22 crossref_primary_10_1038_s41598_023_41581_9 crossref_primary_10_3390_antibiotics13121132 crossref_primary_10_1080_10406638_2022_2160773 crossref_primary_10_1088_2516_1091_ad1cd6 crossref_primary_10_3390_ph16050744 crossref_primary_10_4167_jbv_2025_55_2_091 crossref_primary_10_1128_spectrum_03212_23 crossref_primary_10_1089_phage_2024_0005 crossref_primary_10_3390_ijms242015493 crossref_primary_10_1134_S0026261725601083 crossref_primary_10_3390_antibiotics11060712 crossref_primary_10_1155_cjid_1542576 crossref_primary_10_1128_spectrum_00427_24 crossref_primary_10_46889_JCIM_2025_6207 crossref_primary_10_1089_fpd_2024_0130 crossref_primary_10_1371_journal_pbio_3002952 crossref_primary_10_1128_aac_00578_23 crossref_primary_10_3389_fcimb_2024_1336821 crossref_primary_10_17816_dv629498 crossref_primary_10_1038_s41598_024_59444_2 crossref_primary_10_1128_spectrum_00295_23 crossref_primary_10_3390_antibiotics11070959 crossref_primary_10_1080_1744666X_2023_2233700 crossref_primary_10_3390_pathogens13010076 |
| Cites_doi | 10.1080/14787210.2017.1308251 10.1038/s41467-017-00492-w 10.1038/s41522-021-00195-7 10.1128/AEM.01209-19 10.3390/v11010088 10.1128/AAC.01743-18 10.1128/AAC.00993-20 10.1016/B978-0-08-100205-6.00002-1 10.3390/antibiotics10070849 10.3390/v10070351 10.1128/mSystems.00756-19 10.3389/fmed.2017.00094 10.1007/978-1-60327-164-6_9 10.1016/j.ijantimicag.2018.09.006 10.1016/j.biomaterials.2012.05.031 10.1056/NEJMp048093 10.33073/pjm-2014-019 10.1093/emph/eoy005 10.1021/acsmedchemlett.9b00595 10.1046/j.1365-2672.1998.853541.x 10.1128/JB.00257-06 10.1186/s13756-019-0533-3 10.1016/j.tim.2015.12.011 10.1371/journal.pone.0051017 10.1128/MMBR.00016-10 10.1155/2018/4657396 10.1016/j.clinthera.2020.07.014 10.1128/AAC.00461-20 10.1128/AAC.01863-20 10.3389/fmicb.2018.02348 10.1007/s00018-011-0689-3 10.3390/antibiotics9010002 10.3390/antibiotics3030270 10.3390/antibiotics9050268 10.1126/science.283.5409.1837 10.1111/j.0022-2720.2004.01348.x 10.1038/ismej.2017.190 10.1128/JCM.37.6.1771-1776.1999 10.1128/AAC.00315-18 10.1038/nmicrobiol.2016.194 10.1128/AAC.01879-21 10.1099/00221287-147-1-3 10.1111/1469-0691.12651 |
| ContentType | Journal Article |
| Copyright | Copyright © 2022 Kebriaei et al. Copyright © 2022 Kebriaei et al. 2022 Kebriaei et al. |
| Copyright_xml | – notice: Copyright © 2022 Kebriaei et al. – notice: Copyright © 2022 Kebriaei et al. 2022 Kebriaei et al. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1128/spectrum.00411-22 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2165-0497 |
| Editor | Kaspar, Justin R |
| Editor_xml | – sequence: 1 givenname: Justin R surname: Kaspar fullname: Kaspar, Justin R |
| ExternalDocumentID | oai_doaj_org_article_bab1b2b597c141a2b32989460475ea46 PMC9045164 00411-22 35348366 10_1128_spectrum_00411_22 |
| Genre | Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: R21 AI163726 |
| GroupedDBID | 53G AAGFI AAUOK AAYXX ADBBV ALMA_UNASSIGNED_HOLDINGS CITATION EJD FF~ FRP GROUPED_DOAJ H13 M~E OK1 RPM RSF AGVNZ CGR CUY CVF ECM EIF NPM BXI EBS FF UCJ 7X8 5PM |
| ID | FETCH-LOGICAL-a504t-d9d54fe0846a0826d5dfa17e76bcce9470b2f6d301f190da5b5a347e01d8f5843 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 33 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000835142100050&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2165-0497 |
| IngestDate | Fri Oct 03 12:48:28 EDT 2025 Tue Sep 30 16:24:30 EDT 2025 Thu Sep 04 18:05:27 EDT 2025 Thu Apr 28 03:17:36 EDT 2022 Thu Apr 03 07:01:06 EDT 2025 Sat Nov 29 01:47:28 EST 2025 Tue Nov 18 22:15:43 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | biofilms MRSA bacteriophages |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. https://creativecommons.org/licenses/by/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a504t-d9d54fe0846a0826d5dfa17e76bcce9470b2f6d301f190da5b5a347e01d8f5843 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 The authors declare no conflict of interest. |
| ORCID | 0000-0003-4019-2679 0000-0002-1094-043X 0000-0003-2220-0081 0000-0002-4891-8625 0000-0001-7171-7015 |
| OpenAccessLink | https://doaj.org/article/bab1b2b597c141a2b32989460475ea46 |
| PMID | 35348366 |
| PQID | 2644947796 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_bab1b2b597c141a2b32989460475ea46 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9045164 proquest_miscellaneous_2644947796 asm2_journals_10_1128_spectrum_00411_22 pubmed_primary_35348366 crossref_citationtrail_10_1128_spectrum_00411_22 crossref_primary_10_1128_spectrum_00411_22 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-04-27 |
| PublicationDateYYYYMMDD | 2022-04-27 |
| PublicationDate_xml | – month: 04 year: 2022 text: 2022-04-27 day: 27 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: 1752 N St., N.W., Washington, DC |
| PublicationTitle | Microbiology spectrum |
| PublicationTitleAbbrev | Microbiol Spectr |
| PublicationTitleAlternate | Microbiol Spectr |
| PublicationYear | 2022 |
| Publisher | American Society for Microbiology |
| Publisher_xml | – name: American Society for Microbiology |
| References | CLSI. (e_1_3_3_42_2) 2020 e_1_3_3_17_2 e_1_3_3_16_2 e_1_3_3_19_2 e_1_3_3_18_2 e_1_3_3_39_2 e_1_3_3_13_2 e_1_3_3_36_2 Gaidhani SV (e_1_3_3_38_2) 2014; 140 e_1_3_3_12_2 e_1_3_3_37_2 e_1_3_3_15_2 e_1_3_3_34_2 e_1_3_3_14_2 e_1_3_3_35_2 e_1_3_3_32_2 e_1_3_3_33_2 e_1_3_3_11_2 e_1_3_3_30_2 Akbari-Ayezloy E (e_1_3_3_6_2) 2017; 9 e_1_3_3_10_2 e_1_3_3_31_2 e_1_3_3_40_2 e_1_3_3_5_2 e_1_3_3_8_2 e_1_3_3_7_2 e_1_3_3_28_2 e_1_3_3_9_2 e_1_3_3_27_2 e_1_3_3_29_2 e_1_3_3_24_2 e_1_3_3_47_2 e_1_3_3_23_2 e_1_3_3_48_2 e_1_3_3_26_2 e_1_3_3_45_2 e_1_3_3_25_2 e_1_3_3_46_2 e_1_3_3_2_2 e_1_3_3_20_2 e_1_3_3_43_2 e_1_3_3_44_2 e_1_3_3_4_2 e_1_3_3_22_2 e_1_3_3_41_2 e_1_3_3_3_2 e_1_3_3_21_2 Parasion, S, Kwiatek, M, Gryko, R, Mizak, L, Malm, A (B14) 2014; 63 Kebriaei, R, Rice, SA, Stamper, KC, Rybak, MJ (B47) 2019; 63 Oechslin, F (B17) 2018; 10 Bolte, S, Talbot, C, Boutte, Y, Catrice, O, Read, ND, Satiat-Jeunemaitre, B (B45) 2004; 214 Sergueev, KV, Filippov, AA, Farlow, J, Su, W, Kvachadze, L, Balarjishvili, N, Kutateladze, M, Nikolich, MP (B42) 2019; 85 Ferriol-González, C, Domingo-Calap, P (B9) 2020; 9 Dey, S, Gudipati, S, Giuliano, C, Zervos, MJ, Monk, JM, Szubin, R, Jorgensen, SCJ, Sakoulas, G, Berti, AD (B36) 2019; 9 Lehman, SM, Mearns, G, Rankin, D, Cole, RA, Smrekar, F, Branston, SD, Morales, S (B44) 2019; 11 Zhvania, P, Hoyle, NS, Nadareishvili, L, Nizharadze, D, Kutateladze, M (B19) 2017; 4 Morrisette, T, Lev, KL, Kebriaei, R, Abdul-Mutakabbir, J, Stamper, KC, Morales, S, Lehman, SM, Canfield, GS, Duerkop, BA, Arias, CA, Rybak, MJ (B28) 2020; 64 Potera, C (B32) 1999; 283 Abraham, S, Kaufman, Y, Perreault, F, Young, R, Bar-Zeev, E (B31) 2021; 7 György, B, Szabó, TG, Pásztói, M, Pál, Z, Misják, P, Aradi, B, László, V, Pállinger, É, Pap, E, Kittel, Á, Nagy, G, Falus, A, Buzás, EI (B23) 2011; 68 Kebriaei, R, Lev, K, Morrisette, T, Stamper, K, Abdul-Mutakabbir, JC, Lehman, SM, Morales, S, Rybak, MJ (B25) 2020; 64 Macià, MD, Rojo-Molinero, E, Oliver, A (B40) 2014; 20 Sharma, D, Misba, L, Khan, AU (B4) 2019; 8 Piechota, M, Kot, B, Frankowska-Maciejewska, A, Grużewska, A, Woźniak-Kosek, A (B6) 2018; 2018 Simmons, M, Drescher, K, Nadell, CD, Bucci, V (B30) 2018; 12 (B41) 2020 Kebriaei, R, Rice, SA, Singh, KV, Stamper, KC, Dinh, AQ, Rios, R, Diaz, L, Murray, BE, Munita, JM, Tran, TT, Arias, CA, Rybak, MJ (B46) 2018; 62 Arciola, CR, Campoccia, D, Speziale, P, Montanaro, L, Costerton, JW (B3) 2012; 33 Akbari-Ayezloy, E, Hosseini-Jazani, N, Yousefi, S, Habibi, N (B5) 2017; 9 Schooling, SR, Beveridge, TJ (B22) 2006; 188 Ceri, H, Olson, ME, Stremick, C, Read, RR, Morck, D, Buret, A (B39) 1999; 37 González, S, Fernández, L, Gutiérrez, D, Campelo, AB, Rodríguez, A, García, P (B33) 2018; 9 Drago, L, Toscano, M, Arts, JJC, Geurts, J (B24) 2017 Simon, K, Pier, W, Krüttgen, A, Horz, H-P (B29) 2021; 10 Lam, AK, Panlilio, H, Pusavat, J, Wouters, CL, Moen, EL, Neel, AJ, Rice, CV (B2) 2020; 11 Mazzocco, A, Waddell, TE, Lingohr, E, Johnson, RP (B43) 2009; 501 B10 Kirby, AE (B26) 2012; 7 Gaidhani, SV, Raskar, AV, Poddar, S, Gosavi, S, Sahu, PK, Pardesi, KR, Bhide, SV, Chopade, BA (B37) 2014; 140 Kebriaei, R, Lev, KL, Stamper, KC, Lehman, SM, Morales, S, Rybak, MJ (B27) 2020; 65 Sutherland, I (B1) 2001; 147 Hughes, KA, Sutherland, IW, Clark, J, Jones, MV (B13) 1998; 85 Luong, T, Salabarria, A-C, Roach, DR (B16) 2020; 42 Luepke, KH, Mohr, JF (B8) 2017; 15 Torres-Barceló, C, Hochberg, ME (B18) 2016; 24 Chan, BK, Turner, PE, Kim, S, Mojibian, HR, Elefteriades, JA, Narayan, D (B20) 2018; 2018 Harper, DR, Parracho, HMRT, Walker, J, Sharp, R, Hughes, G, Werthén, M, Lehman, S, Morales, S (B11) 2014; 3 Toyofuku, M, Cárcamo-Oyarce, G, Yamamoto, T, Eisenstein, F, Hsiao, C-C, Kurosawa, M, Gademann, K, Pilhofer, M, Nomura, N, Eberl, L (B35) 2017; 8 Wenzel, RP (B7) 2004; 351 Tkhilaishvili, T, Lombardi, L, Klatt, A-B, Trampuz, A, Di Luca, M (B12) 2018; 52 Pader, V, Hakim, S, Painter, KL, Wigneshweraraj, S, Clarke, TB, Edwards, AM (B34) 2016; 2 Rodriguez-Gonzalez, RA, Leung, CY, Chan, BK, Turner, PE, Weitz, JS (B21) 2020; 5 Caflisch, KM, Patel, R (B15) 2021; 66 Davies, J, Davies, D (B38) 2010; 74 |
| References_xml | – ident: e_1_3_3_9_2 doi: 10.1080/14787210.2017.1308251 – ident: e_1_3_3_36_2 doi: 10.1038/s41467-017-00492-w – ident: e_1_3_3_32_2 doi: 10.1038/s41522-021-00195-7 – ident: e_1_3_3_43_2 doi: 10.1128/AEM.01209-19 – ident: e_1_3_3_45_2 doi: 10.3390/v11010088 – ident: e_1_3_3_48_2 doi: 10.1128/AAC.01743-18 – volume-title: Performance Standards for Antimicrobial Susceptibility Testing year: 2020 ident: e_1_3_3_42_2 – ident: e_1_3_3_29_2 doi: 10.1128/AAC.00993-20 – ident: e_1_3_3_25_2 doi: 10.1016/B978-0-08-100205-6.00002-1 – ident: e_1_3_3_30_2 doi: 10.3390/antibiotics10070849 – ident: e_1_3_3_18_2 doi: 10.3390/v10070351 – ident: e_1_3_3_22_2 doi: 10.1128/mSystems.00756-19 – ident: e_1_3_3_20_2 doi: 10.3389/fmed.2017.00094 – ident: e_1_3_3_44_2 doi: 10.1007/978-1-60327-164-6_9 – ident: e_1_3_3_13_2 doi: 10.1016/j.ijantimicag.2018.09.006 – ident: e_1_3_3_4_2 doi: 10.1016/j.biomaterials.2012.05.031 – ident: e_1_3_3_8_2 doi: 10.1056/NEJMp048093 – ident: e_1_3_3_15_2 doi: 10.33073/pjm-2014-019 – ident: e_1_3_3_21_2 doi: 10.1093/emph/eoy005 – ident: e_1_3_3_3_2 doi: 10.1021/acsmedchemlett.9b00595 – ident: e_1_3_3_14_2 doi: 10.1046/j.1365-2672.1998.853541.x – ident: e_1_3_3_23_2 doi: 10.1128/JB.00257-06 – ident: e_1_3_3_5_2 doi: 10.1186/s13756-019-0533-3 – ident: e_1_3_3_19_2 doi: 10.1016/j.tim.2015.12.011 – ident: e_1_3_3_27_2 doi: 10.1371/journal.pone.0051017 – ident: e_1_3_3_39_2 doi: 10.1128/MMBR.00016-10 – ident: e_1_3_3_7_2 doi: 10.1155/2018/4657396 – volume: 140 start-page: 665 year: 2014 ident: e_1_3_3_38_2 article-title: Time dependent enhanced resistance against antibiotics & metal salts by planktonic & biofilm form of Acinetobacter haemolyticus MMC 8 clinical isolate publication-title: Indian J Med Res – ident: e_1_3_3_17_2 doi: 10.1016/j.clinthera.2020.07.014 – ident: e_1_3_3_26_2 doi: 10.1128/AAC.00461-20 – ident: e_1_3_3_11_2 – ident: e_1_3_3_28_2 doi: 10.1128/AAC.01863-20 – ident: e_1_3_3_34_2 doi: 10.3389/fmicb.2018.02348 – ident: e_1_3_3_24_2 doi: 10.1007/s00018-011-0689-3 – ident: e_1_3_3_37_2 doi: 10.3390/antibiotics9010002 – ident: e_1_3_3_12_2 doi: 10.3390/antibiotics3030270 – ident: e_1_3_3_10_2 doi: 10.3390/antibiotics9050268 – ident: e_1_3_3_33_2 doi: 10.1126/science.283.5409.1837 – ident: e_1_3_3_46_2 doi: 10.1111/j.0022-2720.2004.01348.x – ident: e_1_3_3_31_2 doi: 10.1038/ismej.2017.190 – ident: e_1_3_3_40_2 doi: 10.1128/JCM.37.6.1771-1776.1999 – ident: e_1_3_3_47_2 doi: 10.1128/AAC.00315-18 – ident: e_1_3_3_35_2 doi: 10.1038/nmicrobiol.2016.194 – ident: e_1_3_3_16_2 doi: 10.1128/AAC.01879-21 – volume: 9 start-page: 1 year: 2017 ident: e_1_3_3_6_2 article-title: Eradication of methicillin resistant S. aureus biofilm by the combined use of fosfomycin and β-chloro-L-alanine publication-title: Iran J Microbiol – ident: e_1_3_3_2_2 doi: 10.1099/00221287-147-1-3 – ident: e_1_3_3_41_2 doi: 10.1111/1469-0691.12651 – volume: 66 year: 2021 ident: B15 article-title: Phage activity against planktonic and biofilm Staphylococcus aureus periprosthetic joint infection isolates publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01879-21 – volume: 15 start-page: 425 year: 2017 end-page: 433 ident: B8 article-title: The antibiotic pipeline: reviving research and development and speeding drugs to market publication-title: Expert Rev Anti Infect Ther doi: 10.1080/14787210.2017.1308251 – volume: 3 start-page: 270 year: 2014 end-page: 284 ident: B11 article-title: Bacteriophages and biofilms publication-title: Antibiotics (Basel doi: 10.3390/antibiotics3030270 – volume: 12 start-page: 531 year: 2018 end-page: 543 ident: B30 article-title: Phage mobility is a core determinant of phage–bacteria coexistence in biofilms publication-title: ISME J doi: 10.1038/ismej.2017.190 – volume: 11 start-page: 88 year: 2019 ident: B44 article-title: Design and preclinical development of a phage product for the treatment of antibiotic-resistant Staphylococcus aureus infections publication-title: Viruses doi: 10.3390/v11010088 – volume: 214 start-page: 159 year: 2004 end-page: 173 ident: B45 article-title: FM-dyes as experimental probes for dissecting vesicle trafficking in living plant cells publication-title: J Microsc doi: 10.1111/j.0022-2720.2004.01348.x – volume: 64 year: 2020 ident: B25 article-title: Bacteriophage-antibiotic combination strategy: an alternative against methicillin-resistant phenotypes of Staphylococcus aureus publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00461-20 – volume: 9 start-page: 2 year: 2019 ident: B36 article-title: Reduced production of bacterial membrane vesicles predicts mortality in ST45/USA600 methicillin-resistant Staphylococcus aureus bacteremia publication-title: Antibiotics (Basel) doi: 10.3390/antibiotics9010002 – volume: 85 start-page: 583 year: 1998 end-page: 590 ident: B13 article-title: Bacteriophage and associated polysaccharide depolymerases–novel tools for study of bacterial biofilms publication-title: J Appl Microbiol doi: 10.1046/j.1365-2672.1998.853541.x – volume: 9 start-page: 268 year: 2020 ident: B9 article-title: Phages for biofilm removal publication-title: Antibiotics (Basel doi: 10.3390/antibiotics9050268 – volume: 140 start-page: 665 year: 2014 end-page: 671 ident: B37 article-title: Time dependent enhanced resistance against antibiotics & metal salts by planktonic & biofilm form of Acinetobacter haemolyticus MMC 8 clinical isolate publication-title: Indian J Med Res – volume: 68 start-page: 2667 year: 2011 end-page: 2688 ident: B23 article-title: Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles publication-title: Cell Mol Life Sci doi: 10.1007/s00018-011-0689-3 – volume: 9 start-page: 2348 year: 2018 ident: B33 article-title: Analysis of different parameters affecting diffusion, propagation and survival of staphylophages in bacterial biofilms publication-title: Front Microbiol doi: 10.3389/fmicb.2018.02348 – volume: 9 start-page: 1 year: 2017 end-page: 10 ident: B5 article-title: Eradication of methicillin resistant S. aureus biofilm by the combined use of fosfomycin and β-chloro-L-alanine publication-title: Iran J Microbiol – volume: 2 start-page: 16194 year: 2016 ident: B34 article-title: Staphylococcus aureus inactivates daptomycin by releasing membrane phospholipids publication-title: Nat Microbiol doi: 10.1038/nmicrobiol.2016.194 – volume: 501 start-page: 81 year: 2009 end-page: 85 ident: B43 article-title: Enumeration of bacteriophages using the small drop plaque assay system publication-title: Methods Mol Biol doi: 10.1007/978-1-60327-164-6_9 – volume: 7 start-page: 26 year: 2021 ident: B31 article-title: Bursting out: linking changes in nanotopography and biomechanical properties of biofilm-forming Escherichia coli to the T4 lytic cycle publication-title: NPJ Biofilms Microbiomes doi: 10.1038/s41522-021-00195-7 – year: 2020 ident: B41 publication-title: Performance Standards for Antimicrobial Susceptibility Testing ;30th Edition ;M100 Retrieved April 1, 2020 ;Clinical & Laboratory Standards Institute – volume: 74 start-page: 417 year: 2010 end-page: 433 ident: B38 article-title: Origins and evolution of antibiotic resistance publication-title: Microbiol Mol Biol Rev doi: 10.1128/MMBR.00016-10 – volume: 147 start-page: 3 year: 2001 end-page: 9 ident: B1 article-title: Biofilm exopolysaccharides: a strong and sticky framework publication-title: Microbiology (Reading) doi: 10.1099/00221287-147-1-3 – volume: 65 year: 2020 ident: B27 article-title: Bacteriophage AB-SA01 cocktail in combination with antibiotics against MRSA-VISA strain in an in vitro pharmacokinetic/pharmacodynamic model publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01863-20 – volume: 10 start-page: 351 year: 2018 ident: B17 article-title: Resistance development to bacteriophages occurring during bacteriophage therapy publication-title: Viruses doi: 10.3390/v10070351 – volume: 33 start-page: 5967 year: 2012 end-page: 5982 ident: B3 article-title: Biofilm formation in Staphylococcus implant infections. A review of molecular mechanisms and implications for biofilm-resistant materials publication-title: Biomaterials doi: 10.1016/j.biomaterials.2012.05.031 – volume: 52 start-page: 842 year: 2018 end-page: 853 ident: B12 article-title: Bacteriophage Sb-1 enhances antibiotic activity against biofilm, degrades exopolysaccharide matrix and targets persisters of Staphylococcus aureus publication-title: Int J Antimicrob Agents doi: 10.1016/j.ijantimicag.2018.09.006 – volume: 63 start-page: 137 year: 2014 end-page: 145 ident: B14 article-title: Bacteriophages as an alternative strategy for fighting biofilm development publication-title: Pol J Microbiol doi: 10.33073/pjm-2014-019 – ident: B10 article-title: Bacteriophage.news . 2019 . Bacteriophages and biofilms . https://www.bacteriophage.news/bacteriophages-and-biofilms/ . Retrieved April 7, 2020 . – volume: 7 year: 2012 ident: B26 article-title: Synergistic action of gentamicin and bacteriophage in a continuous culture population of Staphylococcus aureus publication-title: PLoS One doi: 10.1371/journal.pone.0051017 – volume: 8 start-page: 76 year: 2019 ident: B4 article-title: Antibiotics versus biofilm: an emerging battleground in microbial communities publication-title: Antimicrob Resist Infect Control doi: 10.1186/s13756-019-0533-3 – volume: 2018 start-page: 4657396 year: 2018 ident: B6 article-title: Biofilm formation by methicillin-resistant and methicillin-sensitive Staphylococcus aureus strains from hospitalized patients in Poland publication-title: Biomed Res Int doi: 10.1155/2018/4657396 – volume: 20 start-page: 981 year: 2014 end-page: 990 ident: B40 article-title: Antimicrobial susceptibility testing in biofilm-growing bacteria publication-title: Clin Microbiol Infect doi: 10.1111/1469-0691.12651 – volume: 85 year: 2019 ident: B42 article-title: Correlation of host range expansion of therapeutic bacteriophage Sb-1 with allele state at a hypervariable repeat locus publication-title: Appl Environ Microbiol doi: 10.1128/AEM.01209-19 – volume: 8 start-page: 481 year: 2017 ident: B35 article-title: Prophage-triggered membrane vesicle formation through peptidoglycan damage in Bacillus subtilis publication-title: Nat Commun doi: 10.1038/s41467-017-00492-w – volume: 11 start-page: 473 year: 2020 end-page: 478 ident: B2 article-title: Low-molecular-weight branched polyethyleneimine potentiates ampicillin against MRSA biofilms publication-title: ACS Med Chem Lett doi: 10.1021/acsmedchemlett.9b00595 – volume: 24 start-page: 249 year: 2016 end-page: 256 ident: B18 article-title: evolutionary rationale for phages as complements of antibiotics publication-title: Trends Microbiol doi: 10.1016/j.tim.2015.12.011 – volume: 64 year: 2020 ident: B28 article-title: Bacteriophage-antibiotic combinations for Enterococcus faecium with varying bacteriophage and daptomycin susceptibilities publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00993-20 – volume: 4 start-page: 94 year: 2017 ident: B19 article-title: Phage therapy in a 16-year-old boy with Netherton Syndrome publication-title: Front Med (Lausanne) doi: 10.3389/fmed.2017.00094 – volume: 188 start-page: 5945 year: 2006 end-page: 5957 ident: B22 article-title: Membrane vesicles: an overlooked component of the matrices of biofilms publication-title: J Bacteriol doi: 10.1128/JB.00257-06 – volume: 2018 start-page: 60 year: 2018 end-page: 66 ident: B20 article-title: Phage treatment of an aortic graft infected with Pseudomonas aeruginosa publication-title: Evol Med Public Health doi: 10.1093/emph/eoy005 – start-page: 25 year: 2017 end-page: 39 ident: B24 article-title: 2 - Biofilm formation and the biological response publication-title: Management of Periprosthetic Joint Infections (PJIs). ;Woodhead Publishing – volume: 62 year: 2018 ident: B46 article-title: Influence of inoculum effect on the efficacy of daptomycin monotherapy and in combination with β-lactams against daptomycin-susceptible Enterococcus faecium harboring LiaSR substitutions publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00315-18 – volume: 5 year: 2020 ident: B21 article-title: Quantitative models of phage-antibiotic combination therapy publication-title: mSystems doi: 10.1128/mSystems.00756-19 – volume: 351 start-page: 523 year: 2004 end-page: 526 ident: B7 article-title: The antibiotic pipeline–challenges, costs, and values publication-title: N Engl J Med doi: 10.1056/NEJMp048093 – volume: 42 start-page: 1659 year: 2020 end-page: 1680 ident: B16 article-title: Phage therapy in the resistance era: where do we stand and where are we going? publication-title: Clin Ther doi: 10.1016/j.clinthera.2020.07.014 – volume: 283 start-page: 1837 year: 1999 end-page: 1839 ident: B32 article-title: Forging a link between biofilms and disease publication-title: Science doi: 10.1126/science.283.5409.1837 – volume: 63 year: 2019 ident: B47 article-title: Dalbavancin alone and in combination with ceftaroline against four different phenotypes of Staphylococcus aureus in a simulated pharmacodynamic/pharmacokinetic model publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01743-18 – volume: 10 start-page: 849 year: 2021 ident: B29 article-title: Synergy between Phage Sb-1 and oxacillin against methicillin-resistant Staphylococcus aureus publication-title: Antibiotics (Basel doi: 10.3390/antibiotics10070849 – volume: 37 start-page: 1771 year: 1999 end-page: 1776 ident: B39 article-title: The Calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms publication-title: J Clin Microbiol doi: 10.1128/JCM.37.6.1771-1776.1999 |
| SSID | ssj0001105252 |
| Score | 2.3933625 |
| Snippet | Biofilm-associated multidrug-resistant infections pose significant challenges for antibiotic therapy. The extracellular polymeric matrix of biofilms presents... Bacterial biofilms are difficult to eradicate and can complicate many infections by forming on tissues and medical devices. Phage+antibiotic combinations (PAC)... ABSTRACT Bacterial biofilms are difficult to eradicate and can complicate many infections by forming on tissues and medical devices. Phage+antibiotic... |
| SourceID | doaj pubmedcentral proquest asm2 pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e0041122 |
| SubjectTerms | Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Antimicrobial Chemotherapy Bacteriophages Biofilms Daptomycin - pharmacology Methicillin-Resistant Staphylococcus aureus MRSA Research Article |
| Title | Eradication of Biofilm-Mediated Methicillin-Resistant Staphylococcus aureus Infections In Vitro : Bacteriophage-Antibiotic Combination |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/35348366 https://journals.asm.org/doi/10.1128/spectrum.00411-22 https://www.proquest.com/docview/2644947796 https://pubmed.ncbi.nlm.nih.gov/PMC9045164 https://doaj.org/article/bab1b2b597c141a2b32989460475ea46 |
| Volume | 10 |
| WOSCitedRecordID | wos000835142100050&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2165-0497 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001105252 issn: 2165-0497 databaseCode: DOA dateStart: 20210101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2165-0497 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001105252 issn: 2165-0497 databaseCode: M~E dateStart: 20130101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NaxQxFA-6KHiR-tlttUQQBCF2Jp8zvbWyRQ9bRFT2FpJJQhe6M2VmV-jFm_93XzKzy65IvXiZGSYJCe-9JL-8JL-H0NvCylAKaoiTeXTdZCUpnGLECwboFKYMFUwKNqEuLorZrPyyFeorngnr6YF7wR1bY3NLLeDeKue5oZYlznCZcSW84YlsG1DP1mIqeVfyGJ-NDtuYMAYfp4uL7WrxITJM5SQGyx2ZbkF35qNE2_83rPnnkcmtOeh8Dz0ewCM-7Rv9BN3z9VP0sA8nefMM_Z60xg0-ONwEDAlhfrUg0xSOwzs89fF0e_Sw1OSr7yJ0rJcY8CbIGia1pqpWHTar1sPr83BKq46f-Md82TYn-Kzndm6uL2EYIqd1vHDSQGMwDCuwxE41P0ffzyffPn4iQ5gFYkTGl8SVTvDgM0AiBgCBdMIFkyuvpK0qX4L-LA3SwUgQAD04I6wwjCuf5a4IgF_YCzSqm9rvI0wDDwYgkLXM8spzUxbMSCuEAxQKFYzRuyhzPfSTTqclCC30Wjs6aUdTOkbZWi26GtjKY9CMq7uKvN8Uue6pOu7KfBZ1vckYWbbTD7A9Pdie_pftjdGbtaVo6JVxq8XUvll1OsJMkJwqIc_L3nI2VTHBeMEkpKgdm9ppy25KPb9MzN9lZAOS_OB_NP4QPaLxKkfGCVWv0AjE41-jB9XP5bxrj9B9NSuOUqeC5_TX5BYEnCmv |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Eradication+of+Biofilm-Mediated+Methicillin-Resistant+Staphylococcus+aureus+Infections+In+Vitro%3A+Bacteriophage-Antibiotic+Combination&rft.jtitle=Microbiology+spectrum&rft.au=Kebriaei%2C+Razieh&rft.au=Lev%2C+Katherine+L&rft.au=Shah%2C+Rahi+M&rft.au=Stamper%2C+Kyle+C&rft.date=2022-04-27&rft.pub=American+Society+for+Microbiology&rft.eissn=2165-0497&rft.volume=10&rft.issue=2&rft_id=info:doi/10.1128%2Fspectrum.00411-22&rft.externalDocID=00411-22 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2165-0497&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2165-0497&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2165-0497&client=summon |